evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 71.4%Moderate 2 · 28.6%High 0 · 0%

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in event‐free survival compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in hypersensitivity compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in pancreatitis compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in thromboembolism compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in osteonecrosis compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) showed no clear difference in asparaginase‐associated toxicity compared with PEG‐asparaginase (16 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review